Status
Please wait ...

Details for receptor: FLT3

EndoNet ID: ENR00874

To link to the content of EndoNet use the EndoNet ID that is given on the detail pages in the format ENX0000, where X is a place holder for the type of the component (e. g. R for receptor or C for anatomical structure).
As URL for the linking append this ID to the detail page for this type of component.
For an hormone that would be:

http://endonet.bioinf.med.uni-goettingen.de/hormone/ENH00000

It is also possible to use the search of EndoNet to link to the right detail page. The URL should look like

http://endonet.bioinf.med.uni-goettingen.de/search/ENC00000
If the search pattern is unambigious the user is directed to the corresponding detail page.

Synonyms

  • FL cytokine receptor
  • tyrosine-protein kinase receptor FLT3
  • stem cell tyrosine kinase 1
  • STK-1
  • CD135 antigen
  • STK1
  • FLK2
  • FLT3

General information

  • FMS-like tyrosine kinase-3 (FLT3) is a member of the PDGF-R subfamily of receptor tyrosine kinases. [1]

Links to other resources

UniProt P36888
Ensembl ENST00000380987

Binding hormones

  • FLT3-Ligand
    • FTL3 is a cell-surface receptor for the cytokine FLT3LG. [2]

Anatomical structures with this receptor

  • hematopoietic_stem_cell

    Induced phenotypes

    • hematopoiesis
      • The accumulated data clearly point to FLT3 as an important receptor in early hematopoiesis. [1]
    • Acute myeloid leukemia
      • Deregulated tyrosine kinase activity has long been implicated in the molecular pathogenesis of cancer, including leukemia, and mutant forms of KIT, ABL, and platelet-derived growth factor receptor (PDGF-R) number among the constitutively activated tyrosine kinases that have been identified as causative factors in specific hematologic malignancies. [1]
      • FMS-like tyrosine kinase-3 (FLT3), a member of the PDGF-R subfamily of receptor tyrosine kinases, is the most recent major addition to this list [1]
      • A number of FLT3 activating mutations have been found in leukemia patients and human leukemia-derived cell lines. [1]
      • FLT3 activating mutations occur in 30% of AML cases and are therefore the most common molecular abnormality in that disease. [1]
    • In human hematopoietic cells, FLT3 expression is restricted to the CD34-positive fraction of bone marrow and a smaller fraction of CD34-negative cells destined to become dendritic cells. [1]
Reference